Antiva Biosciences CEO Gail Maderis (L) is passing the baton to Kristine Ball

‘Sleep­ing block­buster’: MPM leads $53M Se­ries E for An­ti­va as biotech seeks sec­ond go at tack­ling HPV 

An­ti­va Bio­sciences has picked up an­oth­er $53 mil­lion to bankroll two key stud­ies of its top­i­cal drug for high-risk HPV in­fec­tions and pre-can­cer­ous le­sions. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.